23.4.2026 15:44:26 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state
The annual general meeting in Thor Medical ASA (the "Company") was held today,
23 April 2026.
All items on the agenda were approved in accordance with the notice. The minutes
will be made available on https://www.thormedical.com/.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium, a key component of next-generation targeted cancer
treatment. Its proprietary production process requires no irradiation or use of
nuclear reactors, and provides a reliable, environmentally friendly and
cost-efficient supply of alpha emitters to the radiopharmaceutical industry.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by fueling
next-generation cancer therapies with high-purity isotopes. Thor Medical is
headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the
ticker symbol TRMED. For more information, visit www.thormedical.com -
http://www.thormedical.com.
CONTACTS
* Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988
05 724, mathias.reierth@thormedical.com
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18875938/7987/Download%20announce
ment%20as%20PDF.pdf